Literature DB >> 1696697

Intracranial chondrosarcoma--case report.

T Miyamori1, H Mizukoshi, K Yamano, N Takayanagi, M Sugino, H Hayase, H Ito.   

Abstract

The authors report the case of a 54-year-old male who was found to have a large intracranial chondrosarcoma at the site from which chondromas had been partially removed twice, 6 and 10 years previously. On the third admission, the second through tenth and the twelfth cranial nerves on the right side were involved. Computed tomographic scans showed a large mass in the right middle and posterior fossae and the right ethmoid sinus. Angiography demonstrated an extradural mass in the right middle fossa. The tumor in the middle and posterior fossae was subtotally removed, and second, third, and eighth cranial nerve function improved postoperatively. Histological examination of tumor specimens showed active proliferation of poorly differentiated cartilagenous cells, suggestive of sarcomatous transformation of the pre-existing chondroma. It is emphasized that chondromas should be removed as completely as possible and that patients must be followed carefully after surgery.

Entities:  

Mesh:

Year:  1990        PMID: 1696697     DOI: 10.2176/nmc.30.263

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  3 in total

1.  Cranial chondrosarcoma and recurrence.

Authors:  Orin G Bloch; Brian J Jian; Isaac Yang; Seunggu J Han; Derick Aranda; Brian J Ahn; Andrew T Parsa
Journal:  Skull Base       Date:  2010-05

Review 2.  A systematic review of intracranial chondrosarcoma and survival.

Authors:  Orin G Bloch; Brian J Jian; Isaac Yang; Seunggu J Han; Derick Aranda; Brian J Ahn; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2009-09-30       Impact factor: 1.961

Review 3.  Intracranial chondrosarcoma: review of the literature and report of 15 cases.

Authors:  A G Korten; H J ter Berg; G H Spincemaille; R T van der Laan; A M Van de Wel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.